Increased dissolution rate and oral bioavailability of hydrophobic drug glyburide tablets produced using supercritical CO2 silica dispersion technology |
| |
| Affiliation: | 1. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, PR China;2. School of Pharmacy, Institute for Science and Technology in Medicine, Keele University, Staffordshire, UK;1. Department of Pharmaceutical Science, University of Michigan, Ann Arbor, MI, USA;2. Department of Pharmaceutical Technology, Gazi University, Etiler-Ankara, Turkey;3. Hospira, Inc., Lake Forest, IL, USA;4. TSRL, Inc., Ann Arbor, MI, USA;1. Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic;2. Clinic of Oral and Maxillofacial Surgery, University Hospital Brno, Brno, Czech Republic;3. Department of Maxillo-Facial Surgery, University Hospital Ostrava, Ostrava, Czech Republic;1. Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), Seville, Spain;2. Centre for Network Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Barcelona, Spain;3. Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona, Spain;4. Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Spain;1. Technische Universität Braunschweig, Institute for Chemical and Thermal Process Engineering (ICTV), Braunschweig, Germany;2. Technische Universität Braunschweig, Institute for Pharmaceutical Technology, Braunschweig, Germany;1. Pfizer Industrial Research Chair on PAT in Pharmaceutical Engineering, Department of Chemical & Biotechnological Engineering, Université de Sherbrooke, Sherbrooke, QC, Canada;2. Process Analytical Sciences Group, Global Technology Services, St-Laurent, Montreal, QC, Canada |
| |
| Abstract: | The aim of this study was to design a silica-supported solid dispersion of a water-insoluble drug, glyburide, to increase its dissolution rate and oral absorption using supercritical fluid (SCF) technology. DSC and PXRD results indicated that the encapsulated drug in the optimal solid dispersion was in an amorphous state and the product was stable for 6 months. Glyburide was adsorbed onto the porous silica, as confirmed by the SEM images and BET analysis. Furthermore, FT-IR spectroscopy confirmed that there was no change in the chemical structure of glyburide after the application of SCF. The glyburide silica-based dispersion could also be compressed into tablet form. In vitro drug release analysis of the silica solid dispersion tablets demonstrated faster release of glyburide compared with the commercial micronized tablet. In an in vivo test, the AUC of the tablets composed of the new glyburide silica-based solid dispersion was 2.01 times greater than that of the commercial micronized glyburide tablets. In conclusion, SCF technology presents a promising approach to prepare silica-based solid dispersions of hydrophobic drugs because of its ability to increase their release and oral bioavailability. |
| |
| Keywords: | Supercritical fluid Silica Glyburide Tablet Dissolution Oral bioavailability |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
